These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 32304281)

  • 21. Frequency of next-generation sequencing, prevalence of targetable mutations and response to targeted therapies amongst patients with metastatic urothelial cancer in Ireland: a multi-centre retrospective study of real-world data.
    Ronan K; Jordan E; Leonard C; McDermott R
    Ir J Med Sci; 2024 Jun; 193(3):1155-1161. PubMed ID: 37947995
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
    Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
    Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Erdafitinib for the treatment of urothelial cancer.
    Marandino L; Raggi D; Giannatempo P; Farè E; Necchi A
    Expert Rev Anticancer Ther; 2019 Oct; 19(10):835-846. PubMed ID: 31544541
    [No Abstract]   [Full Text] [Related]  

  • 24. Fibroblast growth factor receptors across urothelial carcinoma landscape.
    Ertl IE; Shariat SF; Mostafaei H; Ilijazi D; Loriot Y
    Curr Opin Urol; 2020 Jul; 30(4):557-565. PubMed ID: 32452999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort.
    Necchi A; Lo Vullo S; Raggi D; Gloghini A; Giannatempo P; Colecchia M; Mariani L
    Eur Urol Focus; 2019 Sep; 5(5):853-856. PubMed ID: 29525380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [High response rates for erdafitinib in patients with FGFR-mutated urothelial carcinoma following failure of platinum-based chemotherapy].
    Grülllich C
    Urologe A; 2020 Apr; 59(4):478-479. PubMed ID: 32103289
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of Erdafitinib on the Pharmacokinetics of Midazolam and Metformin in Patients With Advanced Solid Tumors Harboring FGFR Gene Alterations.
    Zhu W; Baig M; Naini V; De Meulder M; Akapame S; De Zwart L; Haddish-Berhane N; Triantos S
    Clin Pharmacol Drug Dev; 2024 Oct; 13(10):1164-1176. PubMed ID: 39044705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and Genomic Landscape of FGFR3-Altered Urothelial Carcinoma and Treatment Outcomes with Erdafitinib: A Real-World Experience.
    Guercio BJ; Sarfaty M; Teo MY; Ratna N; Duzgol C; Funt SA; Lee CH; Aggen DH; Regazzi AM; Chen Z; Lattanzi M; Al-Ahmadie HA; Brannon AR; Shah R; Chu C; Lenis AT; Pietzak E; Bochner BH; Berger MF; Solit DB; Rosenberg JE; Bajorin DF; Iyer G
    Clin Cancer Res; 2023 Nov; 29(22):4586-4595. PubMed ID: 37682528
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors.
    Bahleda R; Italiano A; Hierro C; Mita A; Cervantes A; Chan N; Awad M; Calvo E; Moreno V; Govindan R; Spira A; Gonzalez M; Zhong B; Santiago-Walker A; Poggesi I; Parekh T; Xie H; Infante J; Tabernero J
    Clin Cancer Res; 2019 Aug; 25(16):4888-4897. PubMed ID: 31088831
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.
    Ning YM; Suzman D; Maher VE; Zhang L; Tang S; Ricks T; Palmby T; Fu W; Liu Q; Goldberg KB; Kim G; Pazdur R
    Oncologist; 2017 Jun; 22(6):743-749. PubMed ID: 28424325
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
    Qin Q; Patel V; Galsky MD
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of FGFR Alteration Status in Urothelial Tumors.
    Bahlinger V; Eckstein M; Hartmann A; Stöhr R
    Methods Mol Biol; 2023; 2684():283-291. PubMed ID: 37410241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. P4HA2-mediated HIF-1α stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer.
    Li X; Li Y; Liu B; Chen L; Lyu F; Zhang P; He Q; Cheng L; Liu C; Song Y; Xing Y
    FASEB J; 2023 Apr; 37(4):e22840. PubMed ID: 36943397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.
    Souza VC; Monteiro FSM; Maluf FC; Werutsky G; Fabrício VC; Gidekel R; Gandur-Quiroga MN; Freitas MRP; Luz M; Campos-Gomez S; Junior JAR; Bastos DA; Sade JP; da Trindade KM; Mota ACA; Fernandes RC; Ruíz AOB; Pereira E Silva BD; de Oliveira FNG; Cutuli HJ; Nogueira L; Aceituno LFG; Fernandez M; Inman E; Caitano M; Herchenhorn D; Ardila-Salcedo J; Pacheco P; de Jesus RG; Gössling G; Soares A; Fay AP
    Clin Genitourin Cancer; 2024 Oct; 22(5):102174. PubMed ID: 39181783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast Growth Factor Receptor (FGFR) Inhibitors in Urothelial Cancer.
    Garje R; An J; Obeidat M; Kumar K; Yasin HA; Zakharia Y
    Oncologist; 2020 Nov; 25(11):e1711-e1719. PubMed ID: 32790011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of Fibroblast Growth-factor Receptor Gene Alterations at the DNA versus Messenger RNA Level in Advanced Urothelial Cancer: Insights for Clinical Research.
    Necchi A; Raggi D; Volpi CC; Giannatempo P; Colecchia M; Gloghini A
    Eur Urol Focus; 2019 Jul; 5(4):689-692. PubMed ID: 28855072
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.
    Teo MY; Mota JM; Whiting KA; Li HA; Funt SA; Lee CH; Solit DB; Al-Ahmadie H; Milowsky MI; Balar AV; Pietzak E; Dalbagni G; Bochner BH; Ostrovnaya I; Bajorin DF; Rosenberg JE; Iyer G
    Eur Urol; 2020 Dec; 78(6):907-915. PubMed ID: 32753285
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II Study of Erdafitinib in Patients With Tumors With
    Gong J; Mita AC; Wei Z; Cheng HH; Mitchell EP; Wright JJ; Ivy SP; Wang V; Gray RC; McShane LM; Rubinstein LV; Patton DR; Williams PM; Hamilton SR; Alva AS; Tricoli JV; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    JCO Precis Oncol; 2024 Apr; 8():e2300406. PubMed ID: 38603651
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
    Franza A; Pirovano M; Giannatempo P; Cosmai L
    Future Oncol; 2022 Jun; 18(19):2455-2464. PubMed ID: 35387485
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.